Satoshi Miyamoto

Okayama, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Intensified multifactorial intervention leads to long-term benefit on kidney outcomes in advanced diabetic kidney disease: A 10-year follow-up of the DNETT-Japan trial.

Intensified multifactorial intervention leads to long-term benefit on kidney outcomes in advanced diabetic kidney disease: A 10-year follow-up of the DNETT-Japan trial.

Journal: Journal of diabetes investigation

Published: April 12, 2026

Diagnostic performance of SD-ΔRR during physical stressors for identifying diabetic sensorimotor polyneuropathy.

Diagnostic performance of SD-ΔRR during physical stressors for identifying diabetic sensorimotor polyneuropathy.

Journal: Journal of diabetes investigation

Published: April 08, 2026

Cystatin C Confirms the Canagliflozin eGFR Slope Benefit in CANPIONE.

Cystatin C Confirms the Canagliflozin eGFR Slope Benefit in CANPIONE.

Journal: Kidney international reports

Published: October 31, 2025

Efficacy of luseogliflozin for renal function preservation in patients with type 2 diabetes mellitus and impaired renal function: A randomized open-label clinical trial (RESOLUTION study).

Efficacy of luseogliflozin for renal function preservation in patients with type 2 diabetes mellitus and impaired renal function: A randomized open-label clinical trial (RESOLUTION study).

Journal: Journal of diabetes investigation

Published: May 20, 2025

Plasma angiotensin-converting enzyme 2 (ACE2) is a marker for renal outcome of diabetic kidney disease (DKD) (U-CARE study 3).

Plasma angiotensin-converting enzyme 2 (ACE2) is a marker for renal outcome of diabetic kidney disease (DKD) (U-CARE study 3).

Journal: BMJ open diabetes research & care

Published: March 31, 2024

A randomized, open-label, clinical trial examined the effects of canagliflozin on albuminuria and eGFR decline using an individual pre-intervention eGFR slope.

A randomized, open-label, clinical trial examined the effects of canagliflozin on albuminuria and eGFR decline using an individual pre-intervention eGFR slope.

Journal: Kidney international

Published: March 03, 2024

Suramin prevents the development of diabetic kidney disease by inhibiting NLRP3 inflammasome activation in KK-Ay mice.

Suramin prevents the development of diabetic kidney disease by inhibiting NLRP3 inflammasome activation in KK-Ay mice.

Journal: Journal of diabetes investigation

Published: May 05, 2022

Rationale, design and baseline characteristics of the effect of canagliflozin in patients with type 2 diabetes and microalbuminuria in the Japanese population: The CANPIONE study.

Rationale, design and baseline characteristics of the effect of canagliflozin in patients with type 2 diabetes and microalbuminuria in the Japanese population: The CANPIONE study.

Journal: Diabetes, obesity & metabolism

Published: January 21, 2022

Novel Urinary Glycan Biomarkers Predict Cardiovascular Events in Patients With Type 2 Diabetes: A Multicenter Prospective Study With 5-Year Follow Up (U-CARE Study 2).

Novel Urinary Glycan Biomarkers Predict Cardiovascular Events in Patients With Type 2 Diabetes: A Multicenter Prospective Study With 5-Year Follow Up (U-CARE Study 2).

Journal: Frontiers in cardiovascular medicine

Published: February 15, 2021

Dysfunction of CD8 + PD-1 + T cells in type 2 diabetes caused by the impairment of metabolism-immune axis.

Dysfunction of CD8 + PD-1 + T cells in type 2 diabetes caused by the impairment of metabolism-immune axis.

Journal: Scientific reports

Published: March 17, 2020

Randomized trial of an intensified, multifactorial intervention in patients with advanced-stage diabetic kidney disease: Diabetic Nephropathy Remission and Regression Team Trial in Japan (DNETT-Japan).

Randomized trial of an intensified, multifactorial intervention in patients with advanced-stage diabetic kidney disease: Diabetic Nephropathy Remission and Regression Team Trial in Japan (DNETT-Japan).

Journal: Journal of diabetes investigation

Published: February 17, 2020

The hypoglycemia-prevention effect of sensor-augmented pump therapy with predictive low glucose management in Japanese patients with type 1 diabetes mellitus: a short-term study.

The hypoglycemia-prevention effect of sensor-augmented pump therapy with predictive low glucose management in Japanese patients with type 1 diabetes mellitus: a short-term study.

Journal: Diabetology international

Published: June 25, 2019

Showing 1-12 of 17

Last Updated: 09/26/2026